These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


246 related items for PubMed ID: 16260489

  • 1. Live attenuated yellow fever 17D infects human DCs and allows for presentation of endogenous and recombinant T cell epitopes.
    Barba-Spaeth G, Longman RS, Albert ML, Rice CM.
    J Exp Med; 2005 Nov 07; 202(9):1179-84. PubMed ID: 16260489
    [Abstract] [Full Text] [Related]

  • 2. Human cytotoxic T lymphocyte responses to live attenuated 17D yellow fever vaccine: identification of HLA-B35-restricted CTL epitopes on nonstructural proteins NS1, NS2b, NS3, and the structural protein E.
    Co MD, Terajima M, Cruz J, Ennis FA, Rothman AL.
    Virology; 2002 Feb 01; 293(1):151-63. PubMed ID: 11853408
    [Abstract] [Full Text] [Related]

  • 3. Attenuation of recombinant yellow fever 17D viruses expressing foreign protein epitopes at the surface.
    Bonaldo MC, Garratt RC, Marchevsky RS, Coutinho ES, Jabor AV, Almeida LF, Yamamura AM, Duarte AS, Oliveira PJ, Lizeu JO, Camacho LA, Freire MS, Galler R.
    J Virol; 2005 Jul 01; 79(13):8602-13. PubMed ID: 15956601
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of yellow fever virus 17D strain as a new vector for HIV-1 vaccine development.
    Franco D, Li W, Qing F, Stoyanov CT, Moran T, Rice CM, Ho DD.
    Vaccine; 2010 Aug 09; 28(35):5676-85. PubMed ID: 20600494
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The live-attenuated yellow fever vaccine 17D induces broad and potent T cell responses against several viral proteins in Indian rhesus macaques--implications for recombinant vaccine design.
    Mudd PA, Piaskowski SM, Neves PC, Rudersdorf R, Kolar HL, Eernisse CM, Weisgrau KL, de Santana MG, Wilson NA, Bonaldo MC, Galler R, Rakasz EG, Watkins DI.
    Immunogenetics; 2010 Sep 09; 62(9):593-600. PubMed ID: 20607226
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Maturation requirements for dendritic cells in T cell stimulation leading to tolerance versus immunity.
    Tan JK, O'Neill HC.
    J Leukoc Biol; 2005 Aug 09; 78(2):319-24. PubMed ID: 15809288
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity.
    Querec T, Bennouna S, Alkan S, Laouar Y, Gorden K, Flavell R, Akira S, Ahmed R, Pulendran B.
    J Exp Med; 2006 Feb 20; 203(2):413-24. PubMed ID: 16461338
    [Abstract] [Full Text] [Related]

  • 16. Enhancement of dendritic cell-based vaccine potency by anti-apoptotic siRNAs targeting key pro-apoptotic proteins in cytotoxic CD8(+) T cell-mediated cell death.
    Kim JH, Kang TH, Noh KH, Bae HC, Kim SH, Yoo YD, Seong SY, Kim TW.
    Immunol Lett; 2009 Jan 29; 122(1):58-67. PubMed ID: 19135479
    [Abstract] [Full Text] [Related]

  • 17. The yellow fever 17D virus as a platform for new live attenuated vaccines.
    Bonaldo MC, Sequeira PC, Galler R.
    Hum Vaccin Immunother; 2014 Jan 29; 10(5):1256-65. PubMed ID: 24553128
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Immunogenicity of sanofi pasteur tetravalent dengue vaccine.
    Guy B.
    J Clin Virol; 2009 Oct 29; 46 Suppl 2():S16-9. PubMed ID: 19800561
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 13.